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Abstract
Background: Hypoﬁbrinogenaemia is one of the main reasons for development of perioperative coagulopathy during major
paediatric surgery. The aim of this study was to assess whether prophylactic maintenance of higher ﬁbrinogen concentrations
through administration of ﬁbrinogen concentrate would decrease the volume of transfused red blood cell (RBCs).
Methods: In this prospective, randomised, clinical trial, patients aged 6 months to 17 yr undergoing craniosynostosis and
scoliosis surgery received ﬁbrinogen concentrate (30 mg kg−1) at two predeﬁned intraoperative ﬁbrinogen concentrations
[ROTEM® FIBTEM maximum clot ﬁrmness (MCF) of <8 mm (conventional) or <13 mm (early substitution)]. Total volume of
transfused RBCs was recorded over 24 h after start of surgery.
Results: Thirty children who underwent craniosynostosis surgery and 19 children who underwent scoliosis surgery were treated
per protocol. During craniosynostosis surgery, children in the early substitution group received signiﬁcantly less RBCs (median,
28ml kg−1; IQR, 21 to 50ml kg−1) comparedwith the conventional ﬁbrinogen trigger of <8mm (median, 56ml kg−1; IQR, 28 to 62ml
kg−1) (P=0.03). Calculatedblood loss aspercent of estimated total bloodvolumedecreased fromamedianof 160% (IQR, 110–190%) to
a median of 90% (IQR, 78–110%) (P=0.017). No signiﬁcant changes were observed in the scoliosis surgery population. No bleeding
events requiring surgical intervention, postoperative transfusions of RBCs, or treatment-related adverse events were observed.
Conclusions: Intraoperative administration of ﬁbrinogen concentrate using a FIBTEM MCF trigger level of <13 mm can be
successfully used to signiﬁcantly decrease bleeding, and transfusion requirements in the setting of craniosynostosis surgery,
but not scoliosis.
Clinical trial registry number: ClinicalTrials.gov NCT01487837.
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Editor’s key points
• Hypoﬁbrinogenaemia can lead to acquired coagulopathy
after major paediatric surgery.
• The effect of a liberal ﬁbrinogen concentrate treatment
strategyon red blood cell transfusionwas studied in a single
centre randomised study of craniosynostosis and scoliosis
surgery patients.
• Thromboelastometry-guided maintenance of high normal
ﬁbrinogen concentrations reduced blood loss and transfu-
sion in craniosynostosis surgery.
Major paediatric surgery is frequently associated with extensive
blood loss, which increases the risk for morbidity andmortality.1
The risks associated with transfusion highlight the urgent need
for blood conserving strategies, especially in children. These in-
clude implementation of patient blood management programs
with coagulation management.2 3 Both major paediatric ortho-
paedic surgery and craniosynostosis surgery are frequently asso-
ciated with moderate to severe bleeding.4–6 The development of
hypoﬁbrinogenaemia is a major reason for coagulopathic bleed-
ing during craniosynostosis surgery.7 A prospective observation-
al trial in adolescents who underwent major spine surgery
demonstrated that preoperative ﬁbrinogen concentrations pre-
dict mean total perioperative blood loss.4 Thus, restoration of
adequate ﬁbrinogen concentrations plays a major role in main-
tenance of effective haemostasis.
As in most European countries cryoprecipitate is not avail-
able, and fresh frozen plasma (FFP) has demonstrated question-
able efﬁcacy in restoring diminished ﬁbrinogen concentrations
after perioperative bleeding,8–10 administration of puriﬁed ﬁ-
brinogen concentrate has become the standard of care in a num-
ber of countries, including Switzerland. Fibrinogen concentrate is
recommended in the current European guidelines for periopera-
tive bleedingmanagement,11 althoughdata in childrenare rare.7 12
In the previously mentioned studies, targeted ﬁbrinogen admin-
istration was successfully implemented using the ROTEM® FIB-
TEM assay (TEM International, Munich, Germany) to monitor
and guide ﬁbrinogen substitution, applying a trigger level of FIB-
TEM MCF <8 mm.11
The aim of this studywas to assess if earlier substitution of ﬁ-
brinogen without waiting for hypoﬁbrinogenaemia, deﬁned as
FIBTEM MCF <8 mm, decreases blood loss and consequently
transfusion of allogeneic blood products. We hypothesized that
maintenance of baseline ﬁbrinogen concentrations for this popu-
lation13 (ROTEM® trigger of FIBTEM MCF <13 mm) can reduce the
need for transfusion of red blood cells (RBC’s) in two types of
major paediatric surgery.
Methods
Study design and population
This phase IV, prospective, randomised, single-blinded, parallel-
group, stratiﬁed clinical trial was conducted at a single children’s
hospital (University Children’s Hospital, Zurich, Switzerland).
The study was approved by the local ethics committee (KEK-
ZH-No. 2011-0440) and the Swiss Regulatory Medical Authorities
(registration No.: 2011 DR 4222), conducted in accordance with
the Declaration of Helsinki and Good Clinical Practice, and regis-
tered at ClinicalTrials.gov identiﬁer No. NCT01487837.
Eligiblemale and female patients between 6months and 17 yr
of age who were to have elective craniosynostosis or scoliosis
surgery were enrolled between February 2012 and September
2014, if informed consent of one parent was obtained. Craniosy-
nostosis surgery was deﬁned as anterior vault reconstruction
with fronto-orbital advancement, and scoliosis surgery as dorsal
instrumentation of more than 6 segments. Exclusion criteria en-
compassed any diagnosed preexisting congenital or acquired co-
agulation disorder, a medical history consistent with increased
bleeding tendency, ongoing anticoagulation therapy or drug in-
take that could cause bleeding, clinical signs or diagnosis of
acute thromboembolism, participation in another clinical trial,
and pregnant or lactating women.
A telephone randomisation system was used. Before starting
the trial, a randomisation list, stratiﬁed by procedure, was pre-
pared by a statistician and sent to dedicated, trained staff mem-
bers in our hospital pharmacy. After the start of anaesthesia for a
consented study patient, the investigator retrieved the random-
isation group by calling the pharmacy. Patients were randomised
to one of the treatment groups after the start of anaesthesia and
stratiﬁed by type of surgery (craniosynostosis or scoliosis
surgery).
Procedures
All subjects in this study received antiﬁbrinolytic prophylaxis by
administration of tranexamic acid (TXA) at an initial dose of
15 mg kg−1 followed by continuous infusion of 1.5 mg kg−1 h−1
until 3 h after transfer to the paediatric intensive care unit
(PICU). Laboratory investigation (cell count, blood gas analysis,
standard plasmatic coagulation testing, factor XIII, and ROTEM®
analysis) was performed after induction of anaesthesia, at the
start of surgery, and every 60 min thereafter, or more frequently
at the discretion of the anaesthetist in charge, if acute bleeding
was present (Fig. 1). Laboratory testing, including ROTEM® ana-
lyses, was performed at the hospital’s central laboratory with
real-time online access to ROTEM® traces from the operating the-
atre. ROTEM® FIBTEM MCF could usually be obtained within
15 min of blood draw. Fibrinogen concentrate was administered
for ROTEM® FIBTEM MCF <8 mm (conventional group) or
<13 mm (early substitution group), at any intraoperative meas-
urement, independent of the presence of bleeding. The trigger
of <8 mm in the conventional group was established based on
the recommendation from a European guideline,11 and the
concentration of <13mm represents the baseline ﬁbrinogen con-
centrations for this population.13 Fibrinogen concentrate
(Haemocomplettan P, CSL Behring GmbH, Marburg, Germany)
was administered at a dose of 30 mg kg−1 if indicated according
to the predeﬁned FIBTEM concentrations by pump-controlled
i.v. administration over 10 min. This dose and the indication of
acquired hypoﬁbrinogenaemia is within the labelling for this
drug in Switzerland, and likewise published in a European guide-
line for perioperative bleedingmanagement in children.11 FIBTEM
was also performed 10 min after the end of ﬁbrinogen adminis-
tration and ﬁbrinogen concentrate was repeatedly administered
if threshold FIBTEM concentrations were not reached.
Body temperature was continuously monitored and all chil-
dren were kept normothermic during the procedure to ensure
physiologic conditions for haemostasis. Red blood cell concen-
trates (RBCs) were transfused following a strict transfusion proto-
col for haemoglobin concentrations <8 g dl−1 with a 10 g dl−1
haemoglobin concentration target. Transfused RBC volume was
calculated by approximating that transfusion of 4ml kg−1 RBC in-
creases haemoglobin by 1 g dl−1.14 If intraoperative blood salvage
with amechanically processed autologous transfusion (MAT) de-
vice was performed, the autologous blood concentrate was used
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as a replacement for RBCs, using the same dose calculation.
Apheresis platelets were transfused at a dose of 20 ml kg−1 for
platelet count <50 000 μl−1. The concomitant coagulation man-
agement algorithm consisted of administration of factor XIII con-
centrate (Fibrogammin, CSL Behring GmbH, Marburg, Germany),
at a dose of 20 IU kg−1 for intraoperative factor XIII concentrations
<30%, or between 30–60% during an episode of ongoing bleeding
requiring transfusion.
Basicﬂuidmanagement consistedof infusing Ringer’s acetate
solution with 1% glucose (Bichsel AG, Interlaken, Switzerland)
and/or Ringer’s acetate solution (Fresenius Kabi, Oberdorf,
Switzerland), at hourly rates of 10–20 ml kg−1 h−1, while a 4%
succinylated gelatin solution (Physiogel balanced, B Braun AG,
Sempach, Switzerland) or 5% albumin solution (CSL Behring,
Bern, Switzerland) was administered additionally to compensate
for estimated blood loss.
• Eligibility: inclusion/exclusion criteria
• Informed consent enrollment
• Medical history
• Bleeding anamnesis
Day -14 to -1
Screening
Day 0
Day of surgery
Start of anaesthesia
Monitoring und blood withdrawal (Baseline)
Randomization
Start of surgery
Conventional group
Administration of study medication (Fibrinogen concentrate 30 mg kg–1)
ROTEM FIBTEM control 15 minutes after study medication
Additional treatment of coagulopathy if persistent bleeding
and other abnormal laboratory results were observed
Transfusion of RBCs and platelet concentrate according
to transfusion algorithm
End of surgery
Day 1
Day 14
24 h after start of surgery: clinical examination, blood withdrawal,
monitoring of postoperative transfusion requirements,
documentation of SAEs
Documentation if patient has been discharged fom hospital,
length of stay on PICU, SAEs
Transfer to PICU
ROTEM FIBTEM MCF <8mm ROTEM FIBTEM MCF <13mm
Early substitution group
First blood withdrawal after start of surgery;
further blood withdrawals every
60 minutes after start of surgery
or if onset of new, acute bleeding episode
Fig 1 Study design and treatment algorithm. Flowchart showingdetails of clinical steps, assessments performed, and treatment administered throughout the study.
ROTEM, rotational thromboelastometry; ROTEM®, TEM International, Munich, Germany; FIBTEM®, functional ﬁbrinogen assay; MCF, maximum clot ﬁrmness;
PICU, paediatric intensive care unit; SAE, severe adverse event; RBC, red blood cell concentrate.
236 | Haas et al.
After transfer to the PICU, the applied transfusion algorithm
consisted of transfusion of 20ml kg−1 RBCs for haemoglobin con-
centration <7 g dl−1, 20 ml kg−1 for platelets if platelet count
<50 000 μl−1, or transfusion of 20ml kg−1 FFP for signiﬁcant bleed-
ing. This represents the current standard of care in our PICU.
Patients were extubated (if not previously performed intraopera-
tively) and transferred to the general ward at the discretion of the
intensivist in charge. The staff in the PICU were blinded to the
randomisation group. Twenty-four hours after the start of sur-
gery a ﬁnal blood withdrawal was performed and the occurrence
of re-bleeding, postoperative transfusion or coagulation therapy,
or severe adverse events (SAEs) were monitored and documen-
ted. SAEs were deﬁned as any deterioration of patient status
that led to death or occurrence of a life threatening situation,
major disability, prolonged hospitalisation, or anyother clinically
relevant change in a patient status. Events were rated as treat-
ment-emergent if any signs of thromboembolic events were ob-
served. At day 14 after surgery, medical charts were reviewed to
assess discharge status, SAEs, episodes of re-bleeding, or need
for revision surgery in the postoperative period.
Study endpoints
The primary endpoint was the total volume of transfused RBCs
per kg bodyweight (including transfused salvaged autologous
blood) within 24 h after start of surgery. Secondary endpoints in-
cluded requirements for all other transfused blood products, in-
traoperative blood loss based on the estimated total blood
volume (calculated as described by Kearney15), length of stay in
the PICU, discharge status at day 14 after surgery, and occurrence
of bleeding that required revision surgery. Treatment-related ad-
verse events that occurred within 14 days after surgery were as-
sessed and recorded. In accordance with Good Clinical Practice,
the study principal investigator evaluated safety data throughout
the study.
Statistical analysis
Sample size calculation for stratiﬁed procedures was based on
data from our institution, showing a standard deviation of 0.31
of the log10-transformed volume (mL) of transfused RBCs. A clin-
ically meaningful reduction for RBC transfusion was deﬁned as
50% (i.e. 0.3 on the log-scale). A power of 80% and a two-sided
type I error of 0.05 revealed a number of 18 patients per group
using unpaired t-test. For a better estimation of clinical relevance,
30 patients were scheduled for each group.
Continuous data are presented as mean (SD) or median (IQR),
and are compared between groups using the Mann-Whitney
U-test. Categorical data are presented as numberwith percentage
and are compared between groups using the χ2 test or Fisher’s
exact test where appropriate. The effect of maintenance of nor-
mal ﬁbrinogen concentrations on volume of transfused RBCs
was assessed using multiple linear regression, with square root
transformed volume of transfused RBCs as the dependent vari-
able, and maintenance of ﬁbrinogen concentrations at ≥13 mm
FIBTEMMCF and type of surgery as independent variables. Valid-
ity of the linear regression was assessed graphically using Q-Q-
and Tukey-Anscombe plots. Two-sided P<0.05 were considered
statistically signiﬁcant. IBM SPSS Statistics, Version 22.0 (IBM
Corp., Armonk, NY, USA) was used for statistical analyses.
Results
Study subjects
All 57 patients screened for this study were consented, stratiﬁed
and randomised to an intervention group (Fig. 2). Of these, 31
subjects underwent craniosynostosis surgery and 26 subjects
underwent scoliosis surgery. The two intervention groupswithin
both stratiﬁed procedures had similar characteristics and no dif-
ferences in baseline laboratory data, except for a slightly higher
FIBTEM MCF in the early substitution group of the scoliosis sur-
gery stratum (Table 1).
As a result of unexpected changes in the surgical faculty and
subsequent difﬁculties in recruitment, the study was terminated
in October 2014 after 57 (instead of 60) subjects were randomised.
A total of 7 subjects in the scoliosis surgery group did not meet
criteria for substitution of ﬁbrinogen and were excluded from
the ﬁnal analysis. As a result of an unexpected change in the sur-
gical procedure, one child in the craniosynostosis group was ex-
cluded after randomisation, as the procedure and the expected
blood loss were considered not comparable by the surgeon.
Primary and secondary endpoints
The intention-to-treat analysis of all subjects revealed a reduc-
tion in transfusion of RBCs in the early substitution group,
21ml kg−1 (IQR; 13 to 31ml kg−1), compared with the convention-
al group, 28 ml kg−1 (IQR; 18 to 57 ml kg−1) (P=0.13). To adjust for
this confounder, multiple linear regression was performed and
demonstrated that the type of surgery (P<0.001) andmaintenance
of normal ﬁbrinogen concentrations (P=0.02), were independent
predictors of volume of transfused RBCs kg−1 body weight (ad-
justed R-squared 0.57).
In the craniosynostosis surgery group, subjects treated with
ﬁbrinogen concentrate, using a trigger of FIBTEM MCF <13 mm
(early substitution group), received signiﬁcantly less RBCs during
the 24 h after the start of surgery (median, 28 ml kg−1; IQR, 21 to
50ml kg−1), compared with the trigger for ﬁbrinogen substitution
of FIBTEM MCF <8 mm (conventional group; median, 56 ml kg−1;
IQR, 28 to 62 ml kg−1) (P=0.03). A median of 2 RBC Units (IQR, 1–2
Units) was used in the conventional group (2 donor exposures),
and a median of 1 RBC unit (IQR, 1–2 units) were used in the
early substitution group (1 donor exposure) (P=0.13). Autologous
blood transfusion (MAT) was not used in this study group, as no
child fulﬁlled departmental criteria of body weight >10 kg.
Calculated total blood loss based on blood volumewas signiﬁ-
cantly higher in the conventional group (median 160%; IQR, 110–
190%) as compared with the early substitution group (median
90%; IQR, 78–110%) (P=0.02).
In scoliosis surgery, no signiﬁcant differences for transfused
RBCs and MAT were observed between groups (Fig. 3): 6 out of 10
subjects (60%) had no intra or postoperative blood transfusion in
the early substitution group (median 0 ml kg−1; IQR, 0–15 ml
kg−1), as compared with 3 out of 9 (33%) in the conventional
group using a FIBTEM MCF <8 mm (median, 18 ml kg−1; IQR, 0–24
ml kg−1; P=0.21). The proportion ofMAT to transfused blood trans-
fusion RBC volume was small in all children with no signiﬁcant
difference between intervention groups (median 0 ml kg−1 (IQR,
0–5 ml kg−1) vs. median 0 ml kg−1 (IQR, 0–4 ml kg−1)) (P=0.91).
No postoperative transfusion of RBCs occurred in either
group. Platelet transfusion was needed in 2 craniosynostosis sur-
gery subjects intraoperatively, and in one subject in the PICU in
the conventional group, and for one subject intraoperatively in
the early substitution group. Transfusion of FFP occurred once
in both groups in the PICU because of prolonged prothrombin
time, although no clinically relevant bleeding or blood loss
through the drainage tube was noted. For the scoliosis surgery
group, no transfusion of either platelets or FFP was necessary.
The average frequency of administering ﬁbrinogen concen-
trate during surgery was 3 times in both intervention groups for
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craniosynostosis surgery (range 1 to 5). The total dose of adminis-
tered ﬁbrinogen concentrate per subject was a median of 90 mg
kg−1 (IQR, 60–90 mg kg−1) in the conventional group and 90 mg
kg−1 (75–120 mg kg−1) in the early substitution group (P=0.08).
For scoliosis surgery, ﬁbrinogen was administered an average
of 2 times in the early substitution group (range 1 to 3) and one-
time in the conventional group (range from 1 to 2). The relative
total dose of administered ﬁbrinogen concentrate per subject
was a median of 30 mg kg−1 (IQR, 30–60 mg kg−1) in the conven-
tional group and 60mg kg−1 (30–68mg kg−1) in the early substitu-
tion group (P=0.28).
Factor XIII concentrate was administered in 69% (9/13) of sub-
jects in the conventional group and 59% (10/17) of the early sub-
stitution group during craniosynostosis surgery, because of low
factor XIII concentrations and increased bleeding. During scoli-
osis surgery, factor XIII was only needed in 11% (1/9) and 20%
(2/10) of subjects, respectively (not statistically signiﬁcant;
Table 2). Surgical revision or re-bleeding that required post-
operative transfusion during the 24 h after the start of surgery
did not occur. Therewere no between-group differences in length
of stay in the PICU or discharge status at 14 days for both surgical
procedures (Table 2).
No difference in intraoperative ﬂuid administration was ob-
served in the craniosynostosis surgery group, whereas signiﬁ-
cantly less crystalloid and colloid were administered in the
early substitution group of the scoliosis surgery group (Table 1).
Although the study was not powered to detect differences in
safety, no treatment-related adverse events were observed.
Serious adverse events (SAE) were observed in three subjects
who underwent scoliosis surgery; none were determined to be
treatment related. All subjects fully recovered after a prolonged
hospital stay.
Discussion
Early intraoperative ﬁbrinogen substitution, using a trigger level of
ROTEM® FIBTEM MCF <13 mm during craniosynostosis surgery,
can lead to a signiﬁcant and clinically relevant reduction in the
volume of transfused RBC concentrates, as compared with a con-
ventional trigger level of FIBTEMMCF <8mm. Furthermore, calcu-
lated blood loss decreased from a median of 160% of estimated
total blood volume to 90%. In the scoliosis surgery group, the
median amount of transfused RBCs decreased from 18 ml kg−1
to no transfusion, but this changewas not statistically signiﬁcant.
To our knowledge this is the ﬁrst prospective, randomised
controlled study demonstrating the successful use of a
ROTEM®-guided administration of ﬁbrinogen concentrate during
non-cardiac major paediatric surgery. We demonstrated the
novel ﬁnding that a higher threshold for ﬁbrinogen substitution
can reduce blood transfusion in major craniosynostosis surgery.
Blood loss during major craniosynostosis surgery has been re-
ported to vary considerably based on the numbers of sutures in-
volved, the length of surgical time, the age at time of surgery, and
the presence of craniofacial syndromes.16 Notably, the observed
blood loss in our early intervention group (median 90%) is mark-
edly below the data of the aforementioned study, which reports a
Assessed for eligibility
(n=57)
Craniosynostosis surgery
Randomized (n=31)
Scoliosis surgery
Randomized (n=26)
Allocated to receive
fibrinogen concentrate if
FIBTEM MCF <8mm
(n=14)
Received allocated
intervention (n=14)
Did not receive allocated
intervention (n=0)
Analysed (n=13)
Excluded from analysis
(n=1)
Different surgical procedure
Analysed (n=17)
Excluded from analysis
(n=0)
Analysed (n=9)
Excluded from analysis
(n=0)
Analysed (n=10)
Excluded from analysis
(n=0)
Lost to follow up
(n=0)
Lost to follow up
(n=0)
Lost to follow up
(n=0)
Lost to follow up
(n=0)
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Excluded (n=0)
Allocated to receive
fibrinogen concentrate if
FIBTEM MCF <13mm
(n=17)
Received allocated
intervention (n=17)
Did not receive allocated
intervention (n=0)
Allocated to receive
fibrinogen concentrate if
FIBTEM MCF <8mm
(n=14)
Received allocated
intervention (n=9)
Did not receive allocated
intervention (n=5)
FIBTEM trigger was not
reached
Allocated to receive
fibrinogen concentrate if
FIBTEM MCF <13mm
(n=12)
Received allocated
intervention (n=10)
Did not receive allocated
intervention (n=2)
FIBTEM trigger was not
reached
Fig 2 CONSORT diagram ﬂow chart FibPaed study.
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blood loss of 148% of estimated total blood volume for multiple
sutures, and 110% if mono suture or bicoronal synostosis surgery
was performed. To further emphasize the effectiveness of the ap-
plied management investigated in this study, no postoperative
RBC transfusion in any child was necessary. This is in contrast
to published data for children who underwent major craniofacial
surgeries, where postoperative transfusion occurred relatively
frequently (26 to 40%).17–19 A recent review article concluded
that ﬁbrinogen therapy appears to reduce transfusion require-
ments, but data from further high quality studies are urgently
needed to conﬁrm this conclusion.20 Coagulation factor based
treatment algorithms have been successfully implemented in
various clinical settings and may offer a much faster and more
targeted approach to treating coagulopathy.11 21–25
Table 1 Subject characteristics and perioperative data. Data are reported asmedian (IQR) or n (%) as appropriate. Table includes only subjects
treated per protocol. FIBTEM, ROTEM® test assessing ﬁbrinogen polymerisation; A10, amplitude after 10min; MCF, maximum clot ﬁrmness;
aPTT, activated partial thromboplastin time; INR, international normalized ratio, Hb, haemoglobin concentration. *Signiﬁcant difference
between treatment groups (Mann-Whitney U-test)
Trigger to initiate ﬁbrinogen
substitution: FIBTEM MCF
<8 mm
Trigger to initiate (conventional
group) ﬁbrinogen substitution:
FIBTEM MCF <13 mm (early
substitution group)
P Value
Craniosynostosis surgery (n=30)
Females 5 (39) 5 (29) –
Males 8 (61) 12 (71) –
Age (months) 10 (8–12) 10 (8–11) 0.68
Weight (kg) 9.7 (8.6–10.4) 9.1 (8.3–10.6) 0.59
Height (cm) 74 (70–80) 76 (74–79) 0.30
Preoperative data
FIBTEM A10 (mm) 9 (9–12) 10 (7–15) 0.46
FIBTEM MCF (mm) 10 (9–13) 10 (8–17) 0.54
FXIII concentration (%) 78 (61–92) 76 (67–97) 0.95
aPTT (s) 31 (30–34) 31 (30–40) 0.48
INR 1.1 (1.0–1.1) 0.9 (0.9–1.1) 0.48
Plasma ﬁbrinogen concentration (mg dl−1) 180 (159–205) 180 (163–223) 0.68
Platelet count (×109 L−1) 277 (241–321) 281 (230–324) 0.91
Hb (g dl−1) 10.1 (9.7–11.2) 10.0 (9.4–10.6) 0.51
Leukocytes (×106 L−1) 6.7 (5.7–7.6) 6.8 (5.9–9.6) 0.59
Intraoperative data
Total volume of crystalloids (ml kg−1) 68 (49–94) 61 (51–105) 0.90
Total volume of colloids (ml kg−1) 50 (32–87) 39 (20–63) 0.16
Postoperative data
Hb 24 h after start of surgery (g dl−1) 8.7 (7.6–10.3) 7.3 (6.7–9.3) 0.07
Operation data
Operation time (min) 180 (164–214) 165 (150–174) 0.09
Scoliosis surgery (n=19)
Females 6 (67) 3 (30) –
Males 3 (33) 7 (70) –
Age (yr) 12 (9–13) 12 (10–13) 0.84
Weight (kg) 23.9 (16.8–31.1) 31.6 (26.3–35.7) 0.08
Height (cm) 127 (120–135) 141 (128–150) 0.08
Preoperative data
FIBTEM A10 (mm) 8 (7–10) 10 (8–12) 0.05
FIBTEM MCF (mm) 9 (7–11) 11 (9–13) 0.03*
FXIII concentration (%) 64 (49–70) 68 (61–88) 0.18
aPTT (s) 32 (30–34) 34 (30–35) 0.50
INR 1.1 (1.0–1.1) 1.0 (1.0–1.1) 0.24
Plasma ﬁbrinogen concentration (mg dl−1) 190 (145–200) 200 (190–224) 0.10
Platelet count (×109 L−1) 235 (192–257) 246 (184–298) 0.72
Hb (g dl−1) 11.5 (10.8–12.0) 12.3 (10.5–12.6) 0.28
Leukocytes (×106 L−1) 5.6 (4.2–6.4) 4.2 (3.5–4.9) 0.07
Intraoperative data
Total volume of crystalloids (ml kg−1) 73 (47–97) 42 (29–58) 0.01*
Total volume of colloids (ml kg−1) 28 (17–38) 11 (0–24) 0.04*
Postoperative data
Hb 24 h after start of surgery (g dl−1) 8.9 (7.9–10.9) 9.9 (8.7–10.6) 0.66
Operation data
Operation time (min) 182 (161–242) 168 (145–239) 0.55
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The favourable outcome could be attributable to the forma-
tion of a more stable clot, and in consequence, to the mitigation
of severe coagulopathic bleeding. The importance of ﬁbrinogen
and its critical role in the formation of a stable clot and preven-
tion of major perioperative bleeding has been increasingly
described.26–28 Results from a retrospective data analysis demon-
strated that hypoﬁbrinogenaemia is the main underlying reason
for intraoperative coagulopathy during craniosynostosis surgery,
and that administration of ﬁbrinogen concentrate can success-
fully treat acquired bleeding.12 A similar ﬁnding was observed
in a retrospective analysis of a larger cohort of children, who
underwent the same surgical procedure, demonstrating reduced
transfusion requirements if a ROTEM® based treatment algo-
rithmwas applied.7 In this study, ﬁbrinogen concentrate and fac-
tor XIII concentrate were exclusively used to treat intraoperative
coagulopathy, whereby the trigger for ﬁbrinogen substitution
was set at FIBTEM MCF <8 mm. The current European guidelines
for intraoperative bleeding management suggest trigger levels
for initiating ﬁbrinogen substitution at plasma ﬁbrinogen con-
centrations of 150–200 mg dl−1 or ROTEM® FIBTEM MCF ≤7 mm,
but evidence based data in children are sparse. The targeted
ﬁbrinogen concentration in our early substitution group is
about 50% higher than the threshold given in the previously
mentioned European guideline.11 However, the higher trigger
Trigger for fibrinogen substitution:
FIBTEM MCF <8mm
(conventional group)
0
Trigger for fibrinogen substitution:
FIBTEM MCF <13mm
(early substitution group)
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Fig 3 Total amount of transfused RBCs and MAT over 24 h after start of
surgery. FIBTEM®, functional ﬁbrinogen assay of ROTEM®; MCF, maximum
clot ﬁrmness; RBCs, red blood cell concentrate; MAT, mechanically
processed autologous transfusion.
Table 2 Study efﬁcacy endpoints. Data are reported as median (IQR) or number (%) as appropriate. Table includes only patients treated per
protocol. RBCs, red blood cell concentrates; MAT,mechanically processed autologous transfusion; FFP, fresh frozen plasma; PICU, paediatric
intensive care unit. *Signiﬁcant difference between treatment groups (Mann-Whitney U-test or Fisher′s exact test)
Trigger to initiate ﬁbrinogen
substitution: FIBTEM MCF
<8 mm (conventional group)
Trigger to initiate ﬁbrinogen
substitution: FIBTEM MCF <13 mm
(early substitution group)
P Value
Craniosynostosis surgery
Primary endpoint
Total amount of transfused RBCs over 24 h after
start of surgery (ml kg−1)
55.5 (27.5–61.8) 28.2 (21.2–49.9) 0.03*
Secondary endpoints
Total amount of transfused platelet concentrate
over 24 h after start of surgery (ml kg−1)
0 (0–5) 0 (0–0) 0.43
Total amount of transfused FFP over 24 h after start
of surgery (ml kg−1)
0 (0–0) 0 (0–0) 0.97
Administration of FXIII concentrate (%) 9 (69) 10 (59) 0.41
Calculated total blood loss (%) 156.9 (110.5–187.3) 89.7 (77.7–112.9) 0.02*
Length of stay in PICU (days) 1 (1–1) 1 (1–1) 0.59
Length of stay in hospital (days) 9 (9–9) 9 (9–9) 0.54
Surgical revision because of bleeding (%) 0 0 1.0
Scoliosis surgery
Primary endpoint
Total amount of transfused RBCs and MAT over
24 h after start of surgery (ml kg−1)
18.4 (0–23.8) 0 (0–15.3) 0.21
Secondary endpoints
Total amount of transfused MAT (ml kg−1) 0 (0–5.2) 0 (0–4.1) 0.91
Total amount of transfused platelet concentrate
over 24 h after start of surgery (ml kg−1)
0 (0–0) 0 (0–0) 1.0
Total amount of transfused FFP over 24 h after start
of surgery (ml kg−1)
0 (0–0) 0 (0–0) 1.0
Administration of FXIII concentrate (%) 1 (11) 2 (20) 0.54
Calculated total blood loss (%) 51.0 (38.5–69.2) 36.5 (14.9–54.3) 0.17
Length of stay in PICU (days) 1 (1–1) 1 (1–1) 0.50
Length of stay in hospital (days) 8 (6–13) 8 (8–10) 0.57
Surgical revision because of bleeding (%) 0 0 1.0
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was intentionally selected with the aim of avoiding the occur-
rence of hypoﬁbrinogenaemia-induced coagulopathy, which
usually develops rapidly during these procedures. In addition,
the resulting ﬁbrinogen concentrations were still within the
normal range of published reference ranges for ROTEM® in
children,29 and thus unlikely to lead to adverse effects from
overdosing.
Additional factors that were likely to reduce the bleeding
tendency in our patient population include prophylactic use
of antiﬁbrinolytics (TXA) and additional monitoring and substi-
tution of factor XIII concentrations. The clinical beneﬁt of
prophylactic TXA administration to signiﬁcantly decrease peri-
operative bleeding and blood transfusion requirements has
been conﬁrmed for both craniosynostosis and scoliosis paedi-
atric surgery.18 30 31 In contrast, the occurrence of low factor
XIII concentrations appears to be frequently present during
major paediatric surgery,13 but data to support routine substi-
tution for treatment of acute bleeding are not available. How-
ever, there is no doubt that factor XIII is required to form a
stable clot.32 As the applied coagulation management in this
study did not include the routine use of products that provide
a source of FXIII, such as fresh frozen plasma or cryoprecipitate,
we implemented the additional targeted factor XIII substitution
in our local transfusion algorithm.
Effective coagulation management requires a combination of
applied treatment options, surgeon experience and technique,
and the ready availability of diagnostic testing. In this study,
use of ROTEM® thromboelastometry was a main pillar in the
timely measurement and targeted administration of coagulation
factors. In severely bleeding infants, changes in haemostatic pro-
ﬁle develop within minutes, making it impossible to wait for the
results of standard coagulation testing, such as ﬁbrinogen con-
centration in order to determine hypoﬁbrinogenaemia. The clin-
ical use of point-of-care testing has markedly improved this
unacceptable time delay and ROTEM®-guided transfusion algo-
rithms have demonstrated a reduction in the amount of peri-
operative blood transfusion.11 33–35 The FIBTEM test is designed
to evaluate clot ﬁrmness while platelet contribution is chemical-
ly blocked; thus the amplitude reﬂects the ﬁbrin polymerization
process, which is completely different from the method used
in the standard Clauss ﬁbrinogen assay.36 Recent literature
has demonstrated that the amplitude of the FIBTEM test can be
safely assessed and used for diagnostic decisions after only
5 min (A5 value), which would further expedite coagulation
management.37 38
Notably, no differencewas observed in terms of the total dose
of ﬁbrinogen administered between both treatment groups in ei-
ther type of surgery. One could speculate that this demonstrates
the very effective result of the continuous ROTEM®-guided
ﬁbrinogen administration, simply using a higher trigger level
and earlier initiation in the early substitution group.
No SAE related to study treatment was observed in any sub-
ject, which is in accordance with published data that indicate
that ﬁbrinogen concentrate offers a good safety proﬁle and
should not place patients at additional risk for thromboembolic
side effects.8 39
Limitations to the study
The study was designed as a single centre study with a small
sample size per group. As a result of unexpected problems with
scheduled eligible patients, the study was terminated after it
had been prolonged for 9 months (amendment to the study
protocol), which affected the primary power analysis. The
unexpectedly large number of subjects who did not receive any
RBC transfusions further weakened the initial power calculation.
However, statistical analyses have conﬁrmed the assumption
that using a higher ﬁbrinogen concentration to initiate ﬁbrinogen
substitution was linked to a nearly 50% decrease in transfused
RBCs during the 24 h after the start of surgery, which was the pri-
mary endpoint. Another limitation is that the sample size was
too small to provide robust data regarding safety problems and
the study was not powered to evaluate safety. The trigger level
of <13mmFIBTEMMCF in the early substitution groupwas deter-
mined based on our own observations that were performed pre-
viously in this patient population. However, in this study,
baseline FIBTEM MCF tended to be lower than median levels of
our previous study, which resulted in earlier substitution of ﬁ-
brinogen in the early substitution group. Finally, intraoperative
staff and study team members were not blinded to the random-
ization. To mitigate this limitation, we used a strictly-enforced
transfusion algorithm and blinded postoperative caregivers.
Conclusions
This study demonstrated that a higher trigger level for ﬁbrinogen
administration, using a ROTEM® FIBTEM MCF trigger level of <13
mm, can decrease bleeding and the transfusion of RBCs in the
setting of craniofacial surgery. This regimen may be considered
and further investigated as an alternative approach to decrease
paediatric perioperative bleeding in clinical scenarios other
than craniosynostosis surgery, thereby reducing exposure to allo-
geneic blood products.
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